Transcript Document

Driving Innovation
UK Manufacturing Strategy
Progress check - One Year On: NESTA, London
Technology:
High Value Manufacturing
Robin Wilson
Lead Technologist, High Value Manufacturing
29th October 2009
1
Driving Innovation
3.103.40
3.504.10
Pod 1
Pod 2
Pod 3
Pod 4
Pod 5
Global value
chains - UKTI
advanced
engineering
Donald McNeil
Technology - High
value manufacturing,
Robin Wilson,
Technology Strategy
Board
Intangibles
- Designing
Demand
David Godber,
Design Council
Manufacturing Skills –
an interactive session
examining supply
attraction and workforce
development and then
looking at skills for the
future.
Joanna Woolf, Cogent
and Lynn Tomkins
Semta
Low Carbon Industrial
Strategy
Adam Cartwright,
Office for Low
Emission Vehicles
Meet some of the
companies who have
been working
successfully with TSB
Meet some of
the companies
where design
has improved
sales
Manufacturing the
Future: Pat Langford,
Director of
Programmes,
STEMNET will lead a
discussion on promoting
Manufacturing as an
exciting and dynamic
career choice. Meet a
company who are
working hard to inspire
young people.
Meet companies who
are operating
successfully in low
carbon markets
UKTI – meet the
companies
exporting in and
2
Driving Innovation
Who are the Technology Strategy Board
• We are a national body set up to invest in
business innovation
• We are sponsored by Department of Business,
Innovation and Skills (BIS – our hosts today)
• We come from business (and the public sector)
About 100 people, >1200 years of business experience
• We work across business, universities and
Government
• We are responsible for investing £1bn
3
Driving Innovation
We support the full range of business
• We help strengthen the global competitive
position of our leading businesses
• We identify and grow sectors and businesses
with the capacity to become the best in the world
• We nurture the businesses that can succeed in
the growth sectors of tomorrow
4
Driving Innovation
And we make choices
• We don’t pick winners, we pick sectors where
UK businesses can thrive and support innovative
companies in them
• We consider the size of the markets, the
capability of the UK to address them and the
timing
• And the difference our support would make
5
Driving Innovation
How we
deliver
6
Driving Innovation
Technology Inspired Innovation
• We build capability in the
underpinning areas that enable a
sure and effective response to
market needs
–
–
–
–
–
–
Advanced materials
Bioscience
Electronics, photonics and electrical systems
Information and communication technologies
High value manufacturing
Nanotechnology
7
Driving Innovation
Our Tools for Prioritisation and Delivery
• Published Technology Strategies
– To communicate funding priorities and rationale
• eg: High Value Manufacturing Strategy (Sept 2008)
– To provide clear, consistent focus for funding applicants
• Competitions – collaborative R&D projects
• eg: £24m High Value Mfg, launched January 2009
• Additional funding mechanisms
• SBRI for R&D contracts (Government procurement)
• Large (>£5m) CR&D Projects, assessed on individual basis
8
Driving Innovation
Our Investment (Assessment) criteria
Model for success: a convincing “yes” to these 4 questions
Can the UK do it?
Is the idea ‘ready’?
Is there a large market
opportunity?
Can the Technology
Strategy Board make a
difference?
9
Driving Innovation
Manufacturing Strategy
• Working with Industry
• Working with Academia
• Working with Government
• Working together
• Developing a common understanding of
challenges and opportunities
• Prioritising investment in key areas
• Publish Strategy, launch CR&D competitions
10
Driving Innovation
Manufacturing
Through Life
• Not just production
• Interfaces forwards and backwards
Research
Production
Service
Decommission
HIGH VALUE MANUFACTURING
Design &
Development
Sale
Operation
11
Driving Innovation
We are world’s 6th
largest manufacturer
12
Driving Innovation
The Four ‘Pillars’ of the HVM Strategy
Production
Processes
Products
Service
Systems
Value
Systems
The strategy includes key manufacturing activities that enhance
competitive advantage in high wage economies;
…and it recognises that large amounts of value-add and valuecapture occur outside production –
…and that technology may bring innovation in all areas.
13
Driving Innovation
R&D Intensity
Prioritisation .. in areas of high growth + high R&D intensity
14
Growth
Driving Innovation
High Value Manufacturing Competition
• The Step Change in Competitiveness / Value Systems
Competition was launched in January 2009 and invited
businesses in a broad range of industry sectors to form
consortia and compete for funding.
• The aim was for companies to achieve major improvements
of between 25% and 50% relative to their current
performance in areas such as overall manufacturing costs,
whole life-cycle costs, whole life environmental impact and
product performance, durability and reliability.
15
Driving Innovation
January 09 Competition - metrics
• £24M – Step Change in Competitiveness
and Value Systems
• Your Response
– 500 downloads (enquiries)
– 300+ EoIs (>£300M investment requested)
– 87 Full Proposals assessed
– 32 projects shortlisted for funding
16
Driving Innovation
And the results – how the £24m was won
Sector/SIC Group
Number of
projects
TSB
funding
(£m)
TSB Funding
(%)
Bioscience & Healthcare
13
9.1
38
Special Purpose Machinery
8
4.9
20
Automotive
3
3.4
15
Aerospace
2
2.5
10
Electrical
1
1.1
5
Non Ferrous Metals
1
0.9
4
Construction
2
0.8
3
Agrochemicals
1
0.7
3
Environmental
1
0.6
3
Total
32
24
100
17
Driving Innovation
Some of the Winning Consortia
– here today at NESTA
SHIELD Project
HEPTACORE Project
Simon Collins
Mike Whelan
Pete Ellison
Tom Pinto
RAPIDPART Project
Venu Kumar
Russell Owen, Weir Valves
Peter Brown, TWI
BIOCHEMIST Project
Kay McClean
CELL THERAPIES Project
STEP Project
Keith Freebairn
Professor Ian Sutherland
Tina Crombie
18
Driving Innovation
Discussion
• Consortia members – you are our customers !
• Customer satisfaction?
• How did you hear about the competition?
• Is the subject scope (technology) right for you?
• Funding and timescales?
• What do we (TSB & BIS) do right?
• What could we improve on?
• Other contributions & feedback?
19
Driving Innovation
SHIELD
•
Summary: The aim of project SHIELD is to develop novel acetabular and
femoral components that minimise bone resorption. This will be achieved
through a combination of component design and material optimisation by
which the load transfer from prosthesis to bone will attempt to mimic bone
stress levels pre-operation. The objective is to develop an innovative solution
to the problem of stress shielding in hip implants therefore increasing the
efficacy of total hip prostheses by increased life span and a reduced need for
revision surgery after failed implantation.
•
Partners:
–
–
–
–
–
–
Corin Ltd (lead),
Invibio Biomaterial Solutions Ltd,
Durham University
TWI Ltd,
Imorphics Ltd,
Continuum Blue Ltd.
20
Driving Innovation
BIOCHEMIST
•
Title: Biocatalysis and Chemical Engineering for Manufacturing Intensification
and Sustainability - BIOCHEMIST
•
Summary: This project will integrate all phases of bioprocess development
from catalyst discovery and engineering, to process design, through to highly
efficient small footprint manufacture of high value products - enhancing the
efficiency, sustainability and flexibility of chemical manufacture. The principle
objectives of the project are (a) a novel compact reactor system for efficient
continuous chemical manufacture, (b) advanced process design to accelerate
introduction of new bio-manufacturing processes and products (c) new
competitive bioprocesses to prepare unnatural amino acids and chiral amines.
•
Partners:
–
–
–
C -Tech Innovation Ltd (lead),
Ashe Morris Ltd,
Ingenza Ltd.
21
Driving Innovation
STEP
•
Title: Scalable Technology for the Extraction of Pharmaceuticals - STEP
•
Summary: We plan to develop small footprint, versatile, counter-current
chromatography purification technology and methodology which can be
operated at a range of scales in both batch and continuous modes and that
can be inserted into existing process plant and systems. The consortium
will address major production challenges aiming to provide a flexible, low
capital capability driving substantial cost efficiency in both drug
development and drug manufacturing processes.
•
Partners:
–
–
–
–
GlaxoSmithKline Research and Development Ltd (lead)
Brunel University
Pfizer Limited
Dynamic Extractions Ltd.
22
Driving Innovation
MANUFACTURE OF CELL THERAPIES
•
Title: Advanced manufacturing process for the production of individualised
cell therapies
•
Summary: Individualised cell therapies ("ICTs") for the treatment of cancer,
autoimmune disease, and infectious disease are progressing through
regulatory approval for clinical use. ICTs are generally based on natural or
genetically enhanced immune cells with disease-fighting applications and are
therefore distinct from regenerative stem cell therapies. This project aims to
achieve the first advanced cell manufacturing system (the "CellPro
Manufacturing System") to support the routine clinical use of ICTs on a costeffective and convenient basis.
•
Partners:
–
–
–
Cell Medica Ltd (lead)
University College London,
eXmoor pharma concepts ltd.
23
Driving Innovation
RAPIDPART
•
Title: RapidPart - Significant Step Change in the Selective Laser Melting Powder
Bed Process for the Manufacture of High Value Components
•
Summary: RapidPart will deliver step change reductions in the manufacturing cost
of laser powder bed deposition, or Selective Laser Melting (SLM), by significantly
increasing the speed of the process. The targeted 500% increase in processing
speed will enable this high value, flexible and environmentally-friendly process to
become commercially viable for a more widespread range of applications, giving
the UK a technical advantage and world lead in laser additive manufacture.
•
Partners:
–
–
–
–
–
–
–
Weir Valves and Controls UK Ltd (lead)
TWI Ltd (Academic)
Thinklaser Limited,
MTT Technologies Ltd,
SPI Lasers UK Limited
Disenco Limited,
Materialise UK.
24
Driving Innovation
HEPTACORE
•
Title: Commercial manufacture of a novel dual hepatitis vaccine
(Hepatacore)
•
Summary: The aim of this project is the further development and
commercial manufacture of a tandem-core technology (TCT) vaccine
candidate, such that a clinical trial may be undertaken. TCT allows the
insertion of at least two different viral antigens into a single highly
immunogenic recombinant protein. This results in a vaccine which can
deliver immunity to two viruses simultaneously within the confines of a
single construct. This project intends to manufacture commercially a
combined hepatitis A and B vaccine (HAV/HBV).
•
Partners:
–
–
–
iQur Ltd
University College London
Mologic Ltd.
25
Driving Innovation
26
Driving Innovation
Helping you stay competitive
• Manufacturing Strategy
– We believe our September 2008 HVM strategy
(and the Government’s Manufacturing Strategy
published at the same time) remain valid and
relevant, in recession and for recovery.
• Additional Funding
–
–
–
–
£150m Advanced Mfg package (July, Gov’t)
£5m extension to HVM competition (July, TSB)
£1m Technology Inspired Feasibility (Sept, TSB)
Further TSB competitions with significant
manufacturing content planned for 2010.
27
Driving Innovation
http://www.innovateuk.org
e: [email protected]
t: 01793 442938
28